New

Global ETF Survey 2026 Available: How 620 Professionals Select ETFs. Access the Report →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

Access the report

›ETF Issuers›Xtrackers by DWS›XGEN

XGEN

Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF

Passive ETF Equity ESG Theme: Healthcare Technology & Innovation Theme: BioTech & Genomics

The XGEN Exchange Traded Fund (ETF) is provided by Xtrackers by DWS. It is built to track an index: MSCI ACWI IMI Genomic Innovation Select Screened 100 Index. The XGEN ETF provides physical exposure, so by buying it you actually own parts of all the 99 underlying holdings. The dividend policy is capitalization.

$44.34

-$0.76 (-1.69%) yesterday

8:00 AM 11/02/26 Closed

1D price range

$44.34$45.29

52W price range

$31.23$46.30

YTD Perf.

+27.29%

YTD Flows

Annualized volatility

Fund AuM

€13M

Share class AuM

€13M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

IE000KD0BZ68

TER

0.3%

Inception date

7/12/2022

Issuer

Xtrackers by DWS

Benchmark

MSCI ACWI IMI Genomic Innovation Select Screened 100 Index

Replication method

Dividend policy

Capitalization

Compare similar ETFs

ETF Name	1w perf.
IBB iShares Biotechnology ETF	+2.46%
2B78 iShares Healthcare Innovation UCITS ETF	+0.86%
CURE VanEck Genomics and Healthcare Innovators UCITS ETF	+0.21%
GDOC Goldman Sachs Future Health Care Equity ETF	+2.65%
LIV Smart Healthcare Innovation ETF	+3.12%
CIB0 Vaneck Bionic Engineering Ucits ETF	+1.51%
IBBQ Invesco Nasdaq Biotechnology ETF	+2.74%
HTEC Robo Global Healthcare Technology and Innovation ETF	+2.32%
203780 Mirae Asset TIGER NASDAQ BIO ETF	+6.27%
BTEE iShares Nasdaq US Biotechnology UCITS ETF	+2.73%
00678 CAPITAL NASDAQ BIOTECHNOLOGY INDEX ETF	+2.80%
FBT First Trust NYSE Arca Biotechnology Index Fund ETF	+0.85%
FBT First Trust NYSE Arca Biotechnology UCITS ETF	+0.85%
FBT First Trust NYSE Arca Biotechnology ETF	+0.70%
IHE iShares U.S. Pharmaceuticals ETF	+3.89%

API

PerformanceDec 31, 2025 - Nov 2, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 09/30/26

Healthcare

100.00%

Latest XGEN news

European Biotech ETFs Rally as a Hawkish Fed Meets a Catalyst-Heavy Calendar

Moving Markets · September 21, 2026

BioTech & Genomics ETFs Shine Amid Sector Rotation

Moving Markets · July 30, 2024

FAQ about XGEN

XGEN is a passively managed ETF that invests in the World Blended Cap segment.

XGEN tracks the MSCI ACWI IMI Genomic Innovation Select Screened 100 Index - USD, through a full replication replication method.

XGEN carries a total expense ratio (TER) of 0.3%.

XGEN was introduced to the market on July 12, 2022.

Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF, XGEN, is provided by Xtrackers by DWS. Learn more about Xtrackers by DWS here.

XGEN oversees €13M in assets as of November 2, 2026.

XGEN follows a capitalizing, meaning it reinvests income within the fund.

As of September 30, 2026, XGEN has significant geographic allocations in USA, Switzerland and China.

As of September 30, 2026, XGEN focuses largely on Healthcare.

As of September 30, 2026, XGEN holds 99 positions in its portfolio, with 61.92% of assets concentrated in its top 15 holdings.

As of September 30, 2026, XGEN top three holdings include Illumina, Inc., Natera, Inc. and Moderna, Inc..

The base currency of XGEN is USD.

Top 10 holdings

Data as of 09/30/26

Illumina, Inc.

5.83%

Natera, Inc.

5.57%

Moderna, Inc.

4.97%

Agilent Technologies, Inc.

4.96%

Danaher Corp.

4.72%

Lonza Group AG

4.27%

Vertex Pharmaceuticals, Inc.

4.20%

GSK Plc

4.13%

Roche Holding AG

3.93%

Guardant Health, Inc.

3.88%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

Trackinsight Global ETF Survey 2026: ETFs' Next Act: From Access to Selection. Access the report

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF

FAQ about XGEN

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US